Objective: The use of pig hearts can solve the problem of shortage of donor hearts for transplantation. However, targeting rejection by single genetic modification was proven to be ineffective, highlighting the requirement for complex genetic modifications and more effective methods for transgenic animal production. We evaluated here whether hearts of hDAF transgenic pigs generated using our technique sperm-mediated gene transfer (SMGT) will be protected from structural damage, metabolic changes, and mechanical dysfunction during perfusion with human blood. Methods: Hearts from control (C, n = 6) or transgenic (T, n = 5) pigs were perfused ex vivo for 4 h with fresh human blood using the ex vivo working mode system allowing monitoring of the function, metabolism, and structure. Results: Cardiac output (mean ± SEM) was maintained in T constant throughout the experiment, at 3.58 ± 0.36 and 3.83 ± 0.14 l/min after 30 min and 4 h, respectively, while cardiac output decreased to 1.95 ± 0.35 l/min in C after 30 min of perfusion (p <0.01 vs. T). The maximum increase in coronary perfusion pressure was reduced in T to 154 ± 16% as compared to C (237 ± 10%, p <0.001). Myocardial ATP after 4 h was 21.1 ± 1.1 nmol/mg dry wt (similar to initial) in T, while it decreased in C to 17.2 ± 1.4 (p <0.05). Deposition of complement factors C3 and C5b9 was present in C but not in T after perfusion. Conclusion: We have shown that hearts from hDAF transgenic pigs produced by SMGT are protected during perfusion with human blood and are metabolically stable and maintain mechanical function above the threshold level for life support.
- Cardiac function
- Hyperacute rejection
- Transgenic pigs
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine